Literature DB >> 11113095

Increased intestinal permeability precedes the onset of Crohn's disease in a subject with familial risk.

E J Irvine1, J K Marshall.   

Abstract

Increased intestinal permeability to several specific molecular probes has been observed in patients with Crohn's disease and their first-degree relatives. A positive family history is also a potent risk factor for inflammatory bowel disease. Although it has been argued that increased permeability in relatives may confer an increased future risk of developing Crohn's disease, long-term follow-up of such family members has been lacking. We describe a 24-year-old woman with a positive family history of Crohn's disease who had an elevated gut permeability to (51)Cr-EDTA at age 13, as part of a cross-sectional cohort study in patients and their first-degree relatives. She was asymptomatic at the time, and extensive investigation found no evidence of microscopic or macroscopic Crohn's disease. Repeat investigation because of symptom onset at age 21 revealed ileocolonic Crohn's disease, which required treatment with systemic corticosteroids to induce a clinical remission. In this case, a permeability defect was clearly identified to precede the onset of Crohn's disease in a subject at increased risk. This observation provides support for the hypothesis that increased gut permeability to macromolecules is an early step in the pathogenesis of this disorder.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113095     DOI: 10.1053/gast.2000.20231

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  77 in total

Review 1.  A perspective on inflammatory bowel disease in the child and adolescent at the turn of the millennium.

Authors:  C Haller; J Markowitz
Journal:  Curr Gastroenterol Rep       Date:  2001-06

2.  The JAK2 variant rs10758669 in Crohn's disease: altering the intestinal barrier as one mechanism of action.

Authors:  Matthias Prager; Janine Büttner; Verena Haas; Daniel C Baumgart; Andreas Sturm; Martin Zeitz; Carsten Büning
Journal:  Int J Colorectal Dis       Date:  2011-11-09       Impact factor: 2.571

Review 3.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

4.  The N-terminal fragment of chromogranin A, vasostatin-1 protects mice from acute or chronic colitis upon oral administration.

Authors:  Cristiano Rumio; Giuseppina F Dusio; Barbara Colombo; Anna Gasparri; Diego Cardani; Fabrizio Marcucci; Angelo Corti
Journal:  Dig Dis Sci       Date:  2012-01-26       Impact factor: 3.199

5.  Claudin-2 as a mediator of leaky gut barrier during intestinal inflammation.

Authors:  J Luettig; R Rosenthal; C Barmeyer; J D Schulzke
Journal:  Tissue Barriers       Date:  2015-04-03

Review 6.  Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application.

Authors:  Jerrold R Turner
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

Review 7.  Alterations in intestinal permeability.

Authors:  M C Arrieta; L Bistritz; J B Meddings
Journal:  Gut       Date:  2006-10       Impact factor: 23.059

8.  What caused the increase of autoimmune and allergic diseases: a decreased or an increased exposure to luminal microbial components?

Authors:  Xiaofa Qin
Journal:  World J Gastroenterol       Date:  2007-02-28       Impact factor: 5.742

9.  Maternal obesity induces gut inflammation and impairs gut epithelial barrier function in nonobese diabetic mice.

Authors:  Yansong Xue; Hui Wang; Min Du; Mei-Jun Zhu
Journal:  J Nutr Biochem       Date:  2014-04-01       Impact factor: 6.048

10.  LIGHT signals directly to intestinal epithelia to cause barrier dysfunction via cytoskeletal and endocytic mechanisms.

Authors:  Brad T Schwarz; Fengjun Wang; Le Shen; Daniel R Clayburgh; Liping Su; Yingmin Wang; Yang-Xin Fu; Jerrold R Turner
Journal:  Gastroenterology       Date:  2007-02-27       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.